NCT06421142Recruiting
FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer
Application Research of FAPI Positron Emission Tomography(PET)/MRI, 18F-Fluorodeoxyglucose (FDG) PET/MRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 9 May 2024
- Start date
- 2 Aug 2024
- Primary completion date
- 1 Aug 2028
- Lead sponsor
- First Affiliated Hospital of Fujian Medical University
- Diseases
- Bladder cancer
- NCT number
- NCT06421142
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 2 Aug 2024 to the primary completion date, 1 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Exclusion criteria for MIBC diagnostic study
- Combined with other malignant tumors;
- Not receiving surgical treatment;
- Receiving neoadjuvant therapy before surgery;
- Previous allergy to contrast components or similar components;
- Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;
- Incomplete clinicopathological data
- Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study
- Combination of other malignant tumors;
- FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy;
- Prior hypersensitivity to contrast components or similar components;
- Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;
- Incomplete clinicopathological data.
Who the study is looking for
- Inclusion criteria for MIBC diagnostic studies
- Patients with suspected muscle-invasive bladder cancer;
- Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
- Complete clinical laboratory and pathological data.
- Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study
- Patients diagnosed with muscle invasive bladder cancer;
- Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy;
- Complete clinical laboratory and pathological data.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| first hospital affiliated of Fujian medical university Coordinator of this site? Confirm its status | Fuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.